Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Neoplasms

Symptoms and General Pathology

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Nutritional and Metabolic Diseases

Rare Diseases

Kidney Diseases

Adenoma

Kidney Failure, Chronic

Hyperplasia

Hyperaldosteronism

Adrenal Hyperplasia, Congenital

Adrenogenital Syndrome

Hypokalemia

Potassium Deficiency

Syndrome

Renal Insufficiency, Chronic

Renal Insufficiency

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Endocrine System Diseases

Disorders of Sex Development

Congenital Abnormalities

Urogenital Abnormalities

Genetic Diseases, Inborn

Metabolism, Inborn Errors

Steroid Metabolism, Inborn Errors

Metabolic Diseases

Gonadal Disorders

Chronic Disease

Disease Attributes

Water-Electrolyte Imbalance

Chronic Graft Versus Host Disease

Congenital Adrenal Hyperplasia

21-hydroxylase Deficiency

Hyperadrenalism

All Drugs and Chemicals

Channel Blockers

Diuretics

Sodium Channel Blockers

Diuretics, Potassium Sparing

Mineralocorticoid Receptor Antagonists

Mineralocorticoids

Patients treated with mineralocorticoid antagonists or potassium sparing diuretics for primary aldosteronism

Unilateral adrenalectomy in patients with unilateral disease

Troy Puar, MRCP

Troy Puar

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands).

It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.

The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.

Outcome of Patients With Primary Aldosteronism

Long-term Outcomes in Patients With Primary Aldosteronism After Treatment

incidence of new cardiovascular events including acute myocardial infarction, revascularisation percutaneously, coronary artery bypass graft, stroke, admission for congestive cardiac failure, atrial fibrillation

incidence of worsening chronic kidney disease, decline of glomerular filtration rate by 15ml/min from at least 60m/min

rate of decline of glomerular filtration rate

Identify variables that are more common in patients with unilateral disease

Identify variables that are more common in patients with positive blood pressure response

Singapore General Hospital

Changi General Hospital

Blood and Lymph Conditions

Immune System Diseases

Musculoskeletal Diseases

Skin and Connective Tissue Diseases

Digestive System Diseases

Infections

Leukemia

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Uterine Cervical Neoplasms

Arthritis

Arthritis, Juvenile

Inflammatory Bowel Diseases

Intestinal Diseases

Virus Diseases

Papilloma

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Neoplasms, Squamous Cell

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Vaccines

The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.

Licensed quadrivalent HPV vaccine, Gardasil

Jim Buttery

A research project is currently being undertaken looking at Human Papilloma Virus (HPV) vaccination in special risk groups. It aims to see if young women with a chronic illness respond well to the HPV vaccine or whether they may require additional doses to ensure protective immunity. The four valent HPV vaccine protects against HPV types 16 \& 18, cervical cancer and HPV types 6 \& 11, anogenital warts.

The six special risk groups include:

Paediatric Rheumatological Disease Inflammatory Bowel Disease Acute Lymphoblastic Leukaemia Solid Organ Transplant Recipients (kidney and liver) Chronic Renal Disease Bone Marrow Transplants This immunity is measured by antibody levels of the HPV types, which requires a single blood test one month after the final dose of HPV vaccine.

This is compared to healthy controls using antibody response to HPV vaccine. This will assess directly whether these special risk groups respond as well to the HPV vaccine.

Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination

Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result

Brockhoff Foundation Australia

Shepherd Foundation Australia

Murdoch Childrens Research Institute

Doctor Jim Buttery

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Outcome of Patients With Primary Aldosteronism	NCT04428827	Primary Aldoste... Primary Aldoste... Primary Aldoste... Adrenalectomy; ... Mineralocortico... Mineralocortico... Cardiovascular ... Chronic Renal D... Hypokalemia	Unilateral adre...	14 Years - 100 Years	Changi General Hospital
Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination	NCT00964210	Cervical Cancer	Licensed quadri...	12 Years - 26 Years	Murdoch Childrens Research Institute

Spots Global Cancer Trial Database for chronic renal disease